8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Feb 5, 2026·SEC
Arrowhead Pharmaceuticals, Inc.(ARWR)Earnings, Financials & Key Ratios
ARWR•NASDAQ
Price updated Jun 19, 2026
AboutArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.Show more
- Revenue$829M+23258.2%
- EBITDA$122M+121.0%
- Net Income-$2M+99.7%
- EPS (Diluted)-0.01+99.8%
- Gross Margin100%+123.6%
- EBITDA Margin14.74%+100.1%
- Operating Margin11.86%+100.1%
- Net Margin-0.2%+100.0%
- ROE-0.47%+99.8%
ARWR Key Insights
Arrowhead Pharmaceuticals, Inc. (ARWR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 54.6%
- ✓FCF machine: 18.9% free cash flow margin
- ✓Momentum leader: RS Rating 89 (top 11%)
- ✓Strong 5Y sales CAGR of 56.6%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Shares diluted 11.7% in last year
- ✗Expensive at 21.7x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ARWR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ARWR Price & Volume
Arrowhead Pharmaceuticals, Inc. (ARWR) stock price & volume — 10-year historical chart
Loading chart...
ARWR Growth Metrics
Arrowhead Pharmaceuticals, Inc. (ARWR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years115.61%
5 Years56.63%
3 Years50.52%
TTM14.09%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-109.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-50.7%
Return on Capital
10 Years-32.16%
5 Years-31.26%
3 Years-31.94%
Last Year8.83%
ARWR Recent Earnings
Arrowhead Pharmaceuticals, Inc. (ARWR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 3/12 qtrs (30%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.93+14.7%
$1.09
Rev
$74M-0.1%
$74M
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$0.22-63.3%
$0.60
Rev
$264M+23.4%
$214M
Q4 2025
Nov 25, 2025Metric
Actual
Est
EPS
$0.18-61.3%
$0.11
Rev
$256M+46.3%
$175M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.26-34.0%
$0.94
Rev
$28M-82.0%
$154M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.93vs $1.09+14.7% | $74Mvs $74M-0.1% |
| Q1 2026 | Feb 5, 2026 | $0.22vs $0.60-63.3% | $264Mvs $214M+23.4% |
| Q4 2025 | Nov 25, 2025 | $0.18vs $0.11-61.3% | $256Mvs $175M+46.3% |
| Q3 2025 | Aug 7, 2025 | $1.26vs $0.94-34.0% | $28Mvs $154M-82.0% |
Based on last 12 quarters of dataView full earnings history →
ARWR Peer Comparison
Arrowhead Pharmaceuticals, Inc. (ARWR) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 MDGL | 11.66B | 505.75 | -39.36 | 432.05% | -27.32% | -50.15% | 0.59 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 |
Compare ARWR vs Peers
Arrowhead Pharmaceuticals, Inc. (ARWR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARWR Income Statement
Arrowhead Pharmaceuticals, Inc. (ARWR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 31.41M | 16.14M | 168.8M | 87.99M | 138.29M | 243.23M | 240.74M | 3.55M | 829.45M | 622.01M |
Revenue Growth % | 19736.49% | -48.6% | 945.67% | -47.87% | 57.16% | 75.89% | -1.03% | -98.52% | 23258.15% | 14.09% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 10.42M | 12.49M | 18.59M | 0 | 6.37M |
COGS % of Revenue | - | - | - | - | - | 4.28% | 5.19% | 523.66% | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 232.81M▲ 0% | 228.24M▼ 2.0% | -15.04M▼ 106.6% | 829.45M▲ 5613.5% | 615.64M▲ 0% |
Gross Margin % | - | - | - | - | - | 95.72% | 94.81% | -423.66% | 100% | 98.98% |
Gross Profit Growth % | - | - | - | - | - | - | -1.96% | -106.59% | 5613.48% | - |
Operating Expenses | 63.71M | 67.38M | 103.17M | 175.21M | 279.06M | 411.32M | 433.24M | 586.04M | 731.1M | 837.54M |
OpEx % of Revenue | 202.86% | 417.41% | 61.12% | 199.12% | 201.8% | 169.11% | 179.97% | 16503.41% | 88.14% | - |
Selling, General & Admin | 17.46M | 19.08M | 26.54M | 51.66M | 80.08M | 122.82M | 90.93M | 96.82M | 121.92M | 154.38M |
SG&A % of Revenue | 55.6% | 118.22% | 15.72% | 58.72% | 57.91% | 50.49% | 37.77% | 2726.56% | 14.7% | - |
Research & Development | 46.25M | 48.3M | 76.63M | 123.54M | 198.98M | 288.5M | 342.31M | 489.22M | 607.16M | 681.64M |
R&D % of Revenue | 147.26% | 299.19% | 45.4% | 140.4% | 143.89% | 118.61% | 142.19% | 13776.85% | 73.2% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.03M | 1.51M |
Operating Income | -37M▲ 0% | -55.94M▼ 51.2% | 61.19M▲ 209.4% | -93.16M▼ 252.2% | -149.04M▼ 60.0% | -178.51M▼ 19.8% | -205M▼ 14.8% | -601.08M▼ 193.2% | 98.35M▲ 116.4% | -221.9M▲ 0% |
Operating Margin % | -117.79% | -346.52% | 36.25% | -105.87% | -107.77% | -73.39% | -85.16% | -16927.06% | 11.86% | -35.67% |
Operating Income Growth % | 54.74% | -51.2% | 209.39% | -252.24% | -59.98% | -19.77% | -14.84% | -193.21% | 116.36% | - |
EBITDA | -32.31M | -51.24M | 65.63M | -87.22M | -140.77M | -168.09M | -192.51M | -582.49M | 122.27M | -196.53M |
EBITDA Margin % | -102.86% | -317.41% | 38.88% | -99.12% | -101.79% | -69.11% | -79.97% | -16403.41% | 14.74% | -31.6% |
EBITDA Growth % | 58.84% | -58.6% | 228.09% | -232.89% | -61.4% | -19.41% | -14.53% | -202.58% | 120.99% | -101.72% |
D&A (Non-Cash Add-back) | 4.69M | 4.7M | 4.44M | 5.94M | 8.27M | 10.42M | 12.49M | 18.59M | 23.93M | 25.37M |
EBIT | -37M | -55.94M | 61.19M | -93.16M | -140.85M | -172.71M | -188.16M | -580.11M | 140.89M | -187.38M |
Net Interest Income | 415.13K | 1.05M | 6.96M | 9.19M | 6.12M | 5.03M | -3.03M | -9.63M | -52.07M | -45.8M |
Interest Income | 415.13K | 1.05M | 6.96M | 9.19M | 6.12M | 5.03M | 15.3M | 22.72M | 37.29M | 46.63M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 18.33M | 32.35M | 89.36M | 92.43M |
Other Income/Expense | 2.62M | 1.49M | 6.96M | 8.61M | 8.19M | 5.8M | -1.49M | -11.38M | -46.81M | -30.37M |
Pretax Income | -34.38M▲ 0% | -54.45M▼ 58.4% | 68.15M▲ 225.2% | -84.55M▼ 224.1% | -140.85M▼ 66.6% | -172.71M▼ 22.6% | -206.49M▼ 19.6% | -612.46M▼ 196.6% | 51.53M▲ 108.4% | -252.26M▲ 0% |
Pretax Margin % | -109.46% | -337.3% | 40.37% | -96.09% | -101.85% | -71.01% | -85.78% | -17247.54% | 6.21% | -40.56% |
Income Tax | 2.4K | 2.4K | 174K | 2K | 2K | 3.79M | 2.78M | -2.77M | 21.42M | 19.6M |
Effective Tax Rate % | -0.01% | -0% | 0.26% | -0% | -0% | -2.19% | -1.35% | 0.45% | 41.56% | -7.77% |
Net Income | -34.38M▲ 0% | -54.45M▼ 58.4% | 67.97M▲ 224.8% | -84.55M▼ 224.4% | -140.85M▼ 66.6% | -176.06M▼ 25.0% | -205.28M▼ 16.6% | -599.49M▼ 192.0% | -1.63M▲ 99.7% | -300.91M▲ 0% |
Net Margin % | -109.46% | -337.31% | 40.27% | -96.09% | -101.85% | -72.39% | -85.27% | -16882.37% | -0.2% | -48.38% |
Net Income Growth % | 57.93% | -58.38% | 224.84% | -224.39% | -66.58% | -25% | -16.59% | -192.04% | 99.73% | -109.01% |
Net Income (Continuing) | -34.38M | -54.45M | 67.97M | -84.55M | -140.85M | -176.49M | -209.28M | -609.69M | 30.11M | -271.86M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -555.19K | -555.19K | -555.19K | 0 | 0 | 19.82M | 15.82M | 5.62M | 37.36M | -15.06M |
EPS (Diluted) | -0.47▲ 0% | -0.65▼ 38.3% | 0.69▲ 206.2% | -0.84▼ 221.7% | -1.36▼ 61.9% | -1.67▼ 22.8% | -1.92▼ 15.0% | -5.00▼ 160.4% | -0.01▲ 99.8% | -2.11▲ 0% |
EPS Growth % | 64.93% | -38.3% | 206.15% | -221.74% | -61.9% | -22.79% | -14.97% | -160.42% | 99.76% | -50.7% |
EPS (Basic) | -0.47 | -0.65 | 0.72 | -0.84 | -1.36 | -1.67 | -1.91 | -5.00 | -0.01 | - |
Diluted Shares Outstanding | 73.9M | 83.64M | 98.61M | 100.72M | 103.75M | 105.43M | 106.75M | 119.78M | 133.76M | 142.42M |
Basic Shares Outstanding | 73.15M | 83.64M | 93.86M | 100.72M | 103.75M | 105.43M | 107.31M | 119.78M | 133.76M | 142.42M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ARWR Balance Sheet
Arrowhead Pharmaceuticals, Inc. (ARWR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 67.9M | 78.77M | 265.25M | 322.37M | 384.6M | 405.3M | 419.52M | 695.47M | 950.64M | 1.84B |
Cash & Short-Term Investments | 65.61M | 76.53M | 258.7M | 315.49M | 367.79M | 376.4M | 403.63M | 680.96M | 919.37M | 1.78B |
Cash Only | 24.84M | 30.13M | 221.8M | 143.58M | 184.43M | 108M | 110.89M | 102.69M | 226.55M | 188.52M |
Short-Term Investments | 40.77M | 46.4M | 36.9M | 171.91M | 183.35M | 268.39M | 292.74M | 578.28M | 692.82M | 1.6B |
Accounts Receivable | 67.8K | 327.38K | 661.36K | 845.67K | 10.26M | 1.41M | 0 | 0 | 6.82M | 15.69M |
Days Sales Outstanding | 0.79 | 7.4 | 1.43 | 3.51 | 27.07 | 2.12 | - | - | 3 | 36.83 |
Inventory | 867.36K | 1.27M | 3.32M | 4.25M | 4.36M | -21.61M | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 1.36M | 640.12K | -754.57K | -2.47M | -2.17M | 41.82M | 7.08M | 4.97M | 13.52M | 18.25M |
Total Non-Current Assets | 36.12M | 32.84M | 84.6M | 200.13M | 325.55M | 286.64M | 346.03M | 444.33M | 434.66M | 428.51M |
Property, Plant & Equipment | 15.51M | 13.94M | 23.21M | 47.02M | 66.02M | 168.59M | 335.56M | 431.29M | 426.41M | 417.62M |
Fixed Asset Turnover | 2.02x | 1.16x | 7.27x | 1.87x | 2.09x | 1.44x | 0.72x | 0.01x | 1.95x | 1.47x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 20.46M | 18.76M | 17.06M | 15.36M | 13.66M | 11.96M | 10.26M | 8.56M | 6.86M | 6.01M |
Long-Term Investments | 0 | 0 | 44.18M | 137.49M | 245.59M | 105.87M | 0 | 0 | 0 | 4.7M |
Other Non-Current Assets | 141.92K | 141.92K | 144.15K | 265.36K | 272K | 218K | 210K | 4.48M | 1.39M | 187K |
Total Assets | 104.02M▲ 0% | 111.61M▲ 7.3% | 349.85M▲ 213.5% | 522.5M▲ 49.4% | 710.15M▲ 35.9% | 691.94M▼ 2.6% | 765.55M▲ 10.6% | 1.14B▲ 48.9% | 1.39B▲ 21.5% | 2.27B▲ 0% |
Asset Turnover | 0.30x | 0.14x | 0.48x | 0.17x | 0.19x | 0.35x | 0.31x | 0.00x | 0.60x | 0.37x |
Asset Growth % | -18.84% | 7.29% | 213.45% | 49.35% | 35.91% | -2.56% | 10.64% | 48.89% | 21.54% | 180.16% |
Total Current Liabilities | 18.7M | 12.36M | 97.07M | 40.68M | 146.54M | 138.85M | 105.46M | 103.17M | 195.49M | 295.22M |
Accounts Payable | 4.08M | 2.81M | 7.65M | 6.83M | 9.46M | 2.87M | 35.87M | 11.39M | 17.67M | 30.75M |
Days Payables Outstanding | - | - | - | - | - | 100.45 | 1.05K | 223.53 | - | 1.64K |
Short-Term Debt | 208.51K | 223.82K | 0 | 1.09M | 2.25M | 2.78M | 10.56M | 6.34M | 40M | 47.77M |
Deferred Revenue (Current) | 5.71M | 600 | 77.77M | 19.29M | 111.06M | 74.1M | 866K | 0 | 2.4M | 245.85M |
Other Current Liabilities | 5.31M | 5.4M | 6.7M | 5.41M | 14M | 46.86M | 40.2M | 63.45M | 80.43M | 87.79M |
Current Ratio | 3.63x | 6.37x | 2.73x | 7.92x | 2.62x | 2.92x | 3.98x | 6.74x | 4.86x | 6.23x |
Quick Ratio | 3.58x | 6.27x | 2.70x | 7.82x | 2.59x | 3.07x | 3.98x | 6.74x | 4.86x | 6.23x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.6K |
Total Non-Current Liabilities | 4.45M | 4M | 8.74M | 20.04M | 154.79M | 134.75M | 372.93M | 845.57M | 686.39M | 1.37B |
Long-Term Debt | 2.33M | 2.1M | 0 | 0 | 0 | 0 | 268.33M | 734.54M | 214.88M | 1.23B |
Capital Lease Obligations | 0 | 0 | 0 | 20.04M | 23.3M | 78.8M | 104.61M | 111.03M | 104.11M | 412.04M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2.13M | 1.9M | 3.7M | 0 | 0 | 0 | 0 | 0 | 367.4M | 0 |
Total Liabilities | 23.16M | 16.37M | 105.81M | 60.72M | 301.33M | 273.6M | 478.39M | 948.74M | 881.88M | 1.67B |
Total Debt | 2.53M | 2.33M | 0 | 21.14M | 25.55M | 81.58M | 383.5M | 851.91M | 366.28M | 1.37B |
Net Debt | -22.31M | -27.81M | -221.8M | -122.44M | -158.89M | -26.43M | 272.61M | 749.23M | 139.74M | 1.18B |
Debt / Equity | 0.03x | 0.02x | - | 0.05x | 0.06x | 0.20x | 1.34x | 4.46x | 0.73x | 2.29x |
Debt / EBITDA | - | - | - | - | - | - | - | - | 3.00x | -6.99x |
Net Debt / EBITDA | - | - | -3.38x | - | - | - | - | - | 1.14x | -6.03x |
Interest Coverage | - | - | - | - | - | - | -10.27x | -17.93x | 1.58x | -2.03x |
Total Equity | 80.87M▲ 0% | 95.24M▲ 17.8% | 244.04M▲ 156.2% | 461.78M▲ 89.2% | 408.82M▼ 11.5% | 418.34M▲ 2.3% | 287.16M▼ 31.4% | 191.06M▼ 33.5% | 503.42M▲ 163.5% | 598.92M▲ 0% |
Equity Growth % | -14.9% | 17.77% | 156.23% | 89.23% | -11.47% | 2.33% | -31.36% | -33.47% | 163.48% | 1107.83% |
Book Value per Share | 1.09 | 1.14 | 2.47 | 4.58 | 3.94 | 3.97 | 2.69 | 1.60 | 3.76 | 4.21 |
Total Shareholders' Equity | 81.42M | 95.8M | 244.59M | 461.78M | 408.82M | 398.52M | 271.34M | 185.44M | 466.05M | 613.98M |
Common Stock | 167.16K | 180.88K | 187.88K | 194.75K | 197K | 198K | 200K | 217K | 231K | 236K |
Retained Earnings | -432.82M | -487.27M | -419.29M | -503.84M | -644.69M | -820.75M | -1.03B | -1.63B | -1.63B | -1.73B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -53.19M | -53.19M |
Accumulated OCI | 33.23K | -21.56K | -391.62K | 18.43K | -69K | -136K | -3.22M | 4.75M | 6.44M | 742K |
Minority Interest | -555.19K | -555.19K | -555.19K | 0 | 0 | 19.82M | 15.82M | 5.62M | 37.36M | -15.06M |
ARWR Cash Flow Statement
Arrowhead Pharmaceuticals, Inc. (ARWR) cash flow — operating, investing & free cash flow history
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -23.94M | -47.22M | 173.03M | -95.8M | 171.31M | -136.13M | -153.89M | -462.85M | 179.55M | -36.31M |
Operating CF Margin % | -76.22% | -292.54% | 102.51% | -108.87% | 123.88% | -55.97% | -63.93% | -13034.38% | 21.65% | - |
Operating CF Growth % | 62.84% | -97.27% | 466.42% | -155.37% | 278.82% | -179.46% | -13.05% | -200.77% | 138.79% | 108.45% |
Net Income | -34.38M | -54.45M | 67.97M | -84.55M | -140.85M | -176.49M | -209.28M | -609.69M | 30.11M | -300.91M |
Depreciation & Amortization | 4.69M | 4.7M | 4.44M | 5.94M | 8.27M | 10.42M | 12.49M | 18.59M | 23.93M | 25.37M |
Stock-Based Compensation | 7.89M | 8.45M | 12.39M | 43.38M | 76.67M | 120.89M | 78.13M | 73.97M | 63.37M | 51.5M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -933.88K | -49.07K | 1.07M | 505K | -1.44M | 7.34M | 16.31M | 29.19M | 80.38M | 83.81M |
Working Capital Changes | -1.21M | -5.88M | 87.16M | -61.08M | 228.66M | -98.29M | -51.55M | 25.09M | -18.23M | 70.04M |
Change in Receivables | 7.2K | -259.58K | -334K | -184K | -9.41M | 8.85M | 1.41M | 0 | -56.97M | -63.46M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -451K |
Change in Payables | -3.51M | -1.27M | 4.84M | -821K | 2.63M | -6.59M | 33M | -5.54M | 6.29M | 21.08M |
Cash from Investing | -48.64M | -7.43M | -47.75M | -240.78M | -141.68M | -5.42M | -96.16M | -420.07M | -129.29M | -704.01M |
Capital Expenditures | -7.92M | -1.42M | -12M | -11.95M | -23.57M | -52.78M | -176.74M | -141.47M | -22.67M | -14.57M |
CapEx % of Revenue | 25.21% | 8.8% | 7.11% | 13.58% | 17.04% | 21.7% | 73.42% | 3983.92% | 2.73% | 2.34% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 12.06M | 59.95M | 66.38M | 257.95M | 11.3M | 65.19M | 253.05M | 870.52M | 74.01M | 741.96M |
Debt Issued (Net) | -197.79K | -208.51K | -2.42M | 0 | 0 | 0 | 0 | 392M | -191.37M | 557.04M |
Equity Issued (Net) | 12.42M | 56.59M | 60.52M | 250.48M | 0 | 5.19M | 3.05M | 431.65M | 270.37M | 274.31M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -166.02K | 3.58M | 8.28M | 7.47M | 11.3M | 60M | 250M | 46.87M | -5M | -89.39M |
Net Change in Cash | -60.53M▲ 0% | 5.29M▲ 108.7% | 191.67M▲ 3520.1% | -78.22M▼ 140.8% | 40.85M▲ 152.2% | -76.43M▼ 287.1% | 2.89M▲ 103.8% | -8.21M▼ 384.3% | 123.86M▲ 1609.4% | 2.81M▲ 0% |
Free Cash Flow | -31.86M▲ 0% | -48.64M▼ 52.7% | 161.03M▲ 431.0% | -107.75M▼ 166.9% | 147.75M▲ 237.1% | -188.91M▼ 227.9% | -330.63M▼ 75.0% | -604.32M▼ 82.8% | 156.89M▲ 126.0% | -50.87M▲ 0% |
FCF Margin % | -101.43% | -301.35% | 95.4% | -122.46% | 106.84% | -77.67% | -137.34% | -17018.3% | 18.91% | -8.18% |
FCF Growth % | 53.35% | -52.7% | 431.04% | -166.91% | 237.11% | -227.86% | -75.02% | -82.78% | 125.96% | -630.14% |
FCF per Share | -0.43 | -0.58 | 1.63 | -1.07 | 1.42 | -1.79 | -3.10 | -5.05 | 1.17 | -0.36 |
FCF Conversion (FCF/Net Income) | 0.70x | 0.87x | 2.55x | 1.13x | -1.22x | 0.77x | 0.75x | 0.77x | -110.09x | 0.17x |
Interest Paid | 187.65K | 173.38K | 27K | 0 | 0 | 0 | 0 | 0 | 19K | 0 |
Taxes Paid | 2.4K | 2.4K | 302K | 0 | 2K | 2K | 0 | 3.74M | 0 | 9.91M |
ARWR Key Ratios
Arrowhead Pharmaceuticals, Inc. (ARWR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -39.09% | -61.84% | 40.07% | -23.96% | -32.36% | -42.57% | -58.19% | -250.72% | -0.47% | -55.09% |
Return on Invested Capital (ROIC) | -78.22% | -66.59% | 102.37% | -38.65% | -37.94% | -41.72% | -32.31% | -60.11% | 9.32% | -15.83% |
Gross Margin | - | - | - | - | - | 95.72% | 94.81% | -423.66% | 100% | 98.98% |
Net Margin | -109.46% | -337.31% | 40.27% | -96.09% | -101.85% | -72.39% | -85.27% | -16882.37% | -0.2% | -48.38% |
Debt / Equity | 0.03x | 0.02x | - | 0.05x | 0.06x | 0.20x | 1.34x | 4.46x | 0.73x | 2.29x |
Interest Coverage | - | - | - | - | - | - | -10.27x | -17.93x | 1.58x | -2.03x |
FCF Conversion | 0.70x | 0.87x | 2.55x | 1.13x | -1.22x | 0.77x | 0.75x | 0.77x | -110.09x | 0.17x |
Revenue Growth | 19736.49% | -48.6% | 945.67% | -47.87% | 57.16% | 75.89% | -1.03% | -98.52% | 23258.15% | 14.09% |
Related:ARWR Dividend History·ARWR Revenue History·ARWR Price History·ARWR P/E History·ARWR Financial Ratios·ARWR Institutional Holders
ARWR SEC Filings & Documents
Arrowhead Pharmaceuticals, Inc. (ARWR) SEC filings — annual & quarterly reports (10-K, 10-Q)
ARWR Frequently Asked Questions
Arrowhead Pharmaceuticals, Inc. (ARWR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Arrowhead Pharmaceuticals, Inc. (ARWR) reported $622.0M in revenue for fiscal year 2025. This represents a 812028% increase from $0.1M in 1997.
Arrowhead Pharmaceuticals, Inc. (ARWR) grew revenue by 23258.2% over the past year. This is strong growth.
Arrowhead Pharmaceuticals, Inc. (ARWR) reported a net loss of $300.9M for fiscal year 2025.
Dividend & Returns
Arrowhead Pharmaceuticals, Inc. (ARWR) has a return on equity (ROE) of -0.5%. Negative ROE indicates the company is unprofitable.
Arrowhead Pharmaceuticals, Inc. (ARWR) had negative free cash flow of $50.9M in fiscal year 2025, likely due to heavy capital investments.